Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

161.41 +0.62 (+0.39%)
Delayed Quote Updated: 2:32 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
59 60 Next >
News headline image
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
Via Benzinga
News headline image
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts ↗
Goldman Sachs downgrades Novartis to Neutral, citing a lack of immediate innovative catalysts and limited stock growth potential. 
Via Benzinga
News headline image
NYSE:NVS: good value for what you're paying. ↗
Investors should take notice ofNOVARTIS AG-SPONSORED ADR (NYSE:NVS)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
Uncovering Dividend Opportunities with NYSE:NVS. ↗
Balancing Dividends and Fundamentals: The Case of NOVARTIS AG-SPONSORED ADR (NYSE:NVS). 
Via Chartmill
News headline image
Good technical signals and a possible breakout for NOVARTIS AG-SPONSORED ADR. ↗
The question on everyone's mind: Will NOVARTIS AG-SPONSORED ADR breakout? 
Via Chartmill
News headline image
Why NYSE:NVS is a Top Pick for Dividend Investors. ↗
Why the dividend investor may take a look at NOVARTIS AG-SPONSORED ADR (NYSE:NVS). 
Via Chartmill
News headline image
S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
Topics Stocks
News headline image
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs ↗
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
News headline image
Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study ↗
Novartis announced positive Phase 3 V-MONO study results for Leqvio, showing significant LDL-C reduction in low and moderate ASCVD risk patients, as the company continues to explore its potential in... 
Via Benzinga
News headline image
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
From Lindy Biosciences
Via Business Wire
News headline image
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats ↗
The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process. 
Via Investor's Business Daily
News headline image
Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal ↗
Siemens Healthineers to acquire Novartis' diagnostics division for over €200M, securing a vital supply of radioactive chemicals used in PET scans to enhance its European presence and cancer imaging... 
Via Benzinga
News headline image
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200 ↗
These companies' growth paths should only be briefly interrupted by headwinds. 
Via The Motley Fool
News headline image
Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug ↗
Novartis faces a legal setback as a federal court allows MSN Pharmaceuticals to launch a generic version of Entresto, its top-selling heart-failure drug. The decision pressures Novartis to explore... 
Via Benzinga
News headline image
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 12, 2024) - Investorideas.com, a go-to investing platform covering biotech and... 
Via Newsfile
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
News headline image
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease ↗
Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression.... 
Via Benzinga
News headline image
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs ↗
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells. 
Via Benzinga
Topics Lawsuit
News headline image
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
From FN Media Group LLC
Via GlobeNewswire
News headline image
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife ↗
The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market. 
Via Benzinga
News headline image
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review ↗
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
News headline image
Pharma Leader Beats on Earnings, But Shares Fall
Novartis released its Q2 financial results. It beat expectations on EPS and revenue. However, shares fell, possibly due to bad news on one upcoming drug. 
Via MarketBeat
Topics Intellectual Property
News headline image
Novartis Ag (NVS) Q2 2024 Earnings Call Transcript ↗
NVS earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates ↗
Investors were caught off guard by a decision on the research and development front. 
Via The Motley Fool
News headline image
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday? ↗
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels... 
Via Benzinga
Topics Stocks
News headline image
Novartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key Drugs ↗
Novartis reports strong Q2 results with adjusted EPS of $1.97, up 21% YoY, and sales at $12.51 billion, up 11%. Key drivers include Entresto, Kesimpta, Cosentyx, Kisqali, Leqvio, and Pluvicto. The... 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.